Influence of heparin, protamine and polybrene on the time integral of thrombin generation (endogenous thrombin potential))

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue 1, 1996, Pages 1-10

  Rotteveel, R C ^a   Roozendaal, K J ^a   Weijers, R N M ^a   Eijsman, L ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Endogenous thrombin potential; Heparin neutralization; Polybrene (hexadimethrine); Protamine

Indexed keywords

BLOOD CLOTTING INHIBITOR; HEPARIN; HEXADIMETHRINE BROMIDE; PROTAMINE; THROMBIN;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN ANTAGONISTS; HEXADIMETHRINE; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTAMINES; REFERENCE VALUES; THROMBIN; TIME FACTORS;

EID: 0030069068     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217181     Document Type: Article

References (29)

1. Bjork I, Lindahl U: Mechanism ofthe anticoagulant action of heparin. Mol Cell Biochem 1982;48:161-182.
2. Pieters J. Willems G, Hemker HC, Lindhout T: Inhibition of factor IXa by antithrombin III/heparin during X activation. J Biol Chem 1988;263: 15313-15318.
3. Pieters J. Lindhout T: The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988;72:2048-2052.
4. Béguin S, Mardiguian J. Lindhout T, Hemker HC: The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Thromb Hae-most 1989;61:30-34.
5. Béguin S, Choay J. Hemker HC: The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989;61:397-401.
6. Hemker HC, Béguin S: Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis 1990;20(suppl 1):81-91.
7. Horrow JC: Protamin: A review of its toxicity. Anesth Analg 1985;64: 348-361.
8. Stefaniszyn HJ. Novick RJ. Salerno TA: Toward a better understanding of the hemodynamic effects of protamine and heparin interaction. J Thorac Cardiovasc Surg 1984;87: 678-686.
9. Anido G, Freeman DJ: Heparin assay and protamine titration. Am J Clin Pathol 1981;76:410-415.
10. Akkerman JWN. Runne WC, Sixma JJ. Zimmerman ANE: Improved survival rates in dogs after extracorporeal circulation by improved control of heparin levels. J Thorac Cardiovasc Surg 1973;68:59-65.
11. Ellison N, Ominsky AJ. Wollman H: Is protamine a clinically important anticoagulant? Anesthesiology 1971;35:621-629.
12. Levy JH: Review articel: Anaphylactic reactions during cardiac surgery. Perfusion 1991;6:3-13.
13. Doolan L, McKenzie I, Krafchek J. Parsons B. Buxton B: Protamine sulphate hypersensitivity. Anaesth Intensive Care 1981;9:147-149.
14. Schapira M, Christman BW: Neutralization of heparin by protamine: Time for a change? Circulation 1990;82:1877-1879.
15. Grann VR, Homewood K, Golden W: Polybrene neutralization as a rapid means of monitoring blood heparin levels. Am J Clin Pathol 1972;58:26-32.
16. Marci CD, Prager D: A review ofthe clinical indications for the plasma heparin assay. Am J Clin Pathol 1993;99:546-550.
17. Preston FW, Parker RP: New antiheparin agent (‘polybrene’). Arch Surg 1953;66:545-551.
18. Godai HC: A comparison of two heparin-neutralizing agents: Protamine and polybrene. Scand J Clin Lab Invest 1960;12:446-457.
19. Douglas AS: Therapuetic useof heparin; in Douglas AS (ed): Anticoagulant Therapy. Oxford, Blackwell Scientific, 1962, pp 120-144.
20. Hemker HC. Willems GM. Béguin S: A computer-assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986;56:9-17.
21. Hemker HC, Wielders S, Béguin S: The thrombin potential: in Bouna-meaux H, Samama M, ten Cate JW (eds): Fraxiparine, Second International World Symposium. Recent Pharmacological and Clinical Data. New York, Schattauer, 1990, pp 89-101.
22. Biggs R, Macfarlane RG: Technical Methods; in Biggs R, Macfarlane RG (eds): Human Blood Coagulation. Oxford, Blackwell Scientific, 1953, p 419.
23. Hemker HC, Béguin S: Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost, in press.
24. Béguin S: Thrombinoscopy; thesis. Maastricht, University Limburg, 1987.
25. Rottcvecl RC, Roozendaal KJ. Eijs-man L, Hemker HC: The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 1993;70:959-962.
26. Lindhardt R, Grant A, Cooney C, langen R: Differential anticoagulant activity of heparin fragments prepared using microbial heparinase. J Biol Chem 1982;257:7310-7313.
27. Esposito RA, Culliford AT, Colvin SB, Thomas SJ. Lackner H, Spencer FC: The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary' bypass. J Thorac Cardiovasc Surg 1983;85:174-185.
28. Hemker HC, Béguin S: How to measure the relevant effect of anticoagulant treatment of the coagulability of plasma; in Poller L, Thomson JM (eds): Thrombosis and Its Management. Edinburgh. Churchill Livingstone, 1993, pp 3-14.
29. Lane DA, Lindahl U (eds): Heparin. Chemical and Biological Properties, Clinical Applications. London, Edward Arnold, 1989